(Alliance News) - Healthcare-focused investors Syncona Ltd and Arix Bioscience PLC noted Thursday that portfolio company Autolus Therapeutics Inc has published additional data on its ongoing clinical trial of AUTO3.
Nasdaq-listed Autolus is currently conducting a phase 1/2 trial of its T cell therapy AUTO3 for the treatment of adults with relapsed refractory diffuse large B cell lymphoma.
As of the cut off date of January 21, 18 patients were evaluated for safety and efficacy with 28-day follow ups at the minimum.
The additional data revealed that AUTO3 was generally well tolerated by all patients, with no patients experiencing dose limiting toxicity, and no treatment related deaths.
"The incremental update in the AUTO3 trial presented at the second European CAR T Cell meeting continue to support the encouraging early indications of durability and high level of activity previously reported. Together with the encouraging signs of a manageable safety profile in adult patients with DLBCL, these early data for AUTO3 show the potential for a differentiated product profile," said Autolus Chief Executive Officer Christian Itin.
Syncona holds a stake of 28% in Autolus, while Arix has a 6.5% holding.
Shares in FTSE 250-listed Syncona were up 1.9% at 215.40 pence on Thursday in London. Arix Bioscience's shares were down 2.1% at 94.03p.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
